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Phosphoproteomic Analysis Reveals the
Importance of Kinase Regulation During
Orbivirus Infection*□S
Bjorn-Patrick Mohl‡, Edward Emmott§, and Polly Roy‡¶
Bluetongue virus (BTV) causes infections in wild and do-
mesticated ruminants with high morbidity and mortality
and is responsible for significant economic losses in both
developing and developed countries. BTV serves as a
model for the study of other members of the Orbivirus
genus. Previously, the importance of casein kinase 2 for
BTV replication was demonstrated. To identify intracellu-
lar signaling pathways and novel host-cell kinases in-
volved during BTV infection, the phosphoproteome of BTV
infected cells was analyzed. Over 1000 phosphosites were
identified using mass spectrometry, which were then
used to determine the corresponding kinases involved
during BTV infection. This analysis yielded protein kinase
A (PKA) as a novel kinase activated during BTV infection.
Subsequently, the importance of PKA for BTV infection
was validated using a PKA inhibitor and activator. Our
data confirmed that PKA was essential for efficient viral
growth. Further, we showed that PKA is also required for
infection of equid cells by African horse sickness virus,
another member of the Orbivirus genus. Thus, despite
their preference in specific host species, orbiviruses
may utilize the same host signaling pathways during
their replication. Molecular & Cellular Proteomics 16:
10.1074/mcp.M117.067355, 1990–2005, 2017.
Reversible protein phosphorylation mediated in part by ki-
nases is a ubiquitous mechanism within cells that facilitates
the continual adjustment and tuning of catabolic, anabolic
and signal transduction events to maintain cellular equilibrium
(1). These attributes make kinases an essential component of
host cells to be harnessed for successful viral infection, serv-
ing as a mechanism for the regulation of virus entry, transcrip-
tion, replication, viral RNA binding activity, virus assembly and
egress. Examples include Lassa virus (2), Ebola virus (3, 4),
Junin virus (5), Andes virus (6), human immunodeficiency virus
type 1 (HIV-1) (7), and hepatitis C virus (HCV) (8) where such
modulations facilitate successful infection and replication.
Orbiviruses (Reoviridae family) are vectored to vertebrate
species (e.g. sheep, cattle, horses, deer, etc.) by arthropods
(gnats, ticks, or mosquitoes depending on the virus) hence
determining their geographic distribution. Bluetongue virus
(BTV)1 with 27 serotypes is one of the most widespread
pathogen of ruminants (mortality reaching 70% in sheep) in
many parts of the world and acts as an important represent-
ative of orbiviruses (9). African Horse Sickness virus (AHSV),
which predominantly infects equids with 95% mortality in
horses, is genetically and morphologically like BTV. Replica-
tion of these two viruses in such distinct cell types provides an
opportunity to dissect the critical virus-host interactions that
occur in each. BTV (and AHSV) is a nonenveloped, icosahe-
dral double-capsid virus with an architecturally complex
structure. Surrounding a genome of 10 segmented double-
stranded RNA (dsRNA) genome, are two concentric protein
shells composed of 7 structural proteins (VP1-VP7) (10). Ad-
ditionally, 4 nonstructural proteins (NS1-NS4) are also synthe-
sized in the infected host cells and each plays important roles
in the virus life cycle (11, 12).
Recent studies in our lab have highlighted the significance
of kinases for the BTV life-cycle. Casein kinase 2 (CK2) was
shown to mediate the phosphorylation of the viral protein
NS2. Inhibition of CK2 activity, but not CK1 activity, was
shown to be deleterious to virus replication (13, 14). CK2 has
also been reported to be involved for phosphorylation of one
of the non-structural proteins, NSP5, of Rotavirus, a Reoviri-
dae family member, whereas CK1 was essential for NSP5
hyperphosphorylation (15, 16). Given the limited information
available to date and based on this example of a host kinase
facilitating BTV infection, we interrogated the phosphopro-
teome of BTV infected HeLa cells to identify intracellular sig-
naling pathways and critical host factors activated or sup-
pressed upon BTV infection. A series of kinases were
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identified as a result of BTV infection. We chose one of these
kinases, protein kinase A (PKA), which constituted a novel
host factor that had not been previously associated with BTV.
To determine whether PKA activity held similar significance to
BTV, as had been previously documented for HCV (17), ade-
novirus (18), and Herpes simplex virus 1 (19).
Functional studies using a PKA inhibitor showed impaired
viral replication in both HeLa and sheep PT cells, a natural
host derived cell line. Furthermore, PKA inhibition also served
to impair AHSV replication in HeLa and equid dermal cells, a
natural host derived cell line. Conversely, PKA activation had
the opposite effect on both BTV and AHSV. This similarity in
response may suggest that both BTV and AHSV share a
dependence on these PKA regulated pathways. Further, we
also examined AKT/protein kinase B (PKB) activity, which
featured in our phosphoproteome analysis and that had re-
cently been implicated in mediating autophagy induction by
BTV (20). Our data showed an increase in AKT substrate
phosphorylation during both BTV and AHSV infection, which
in the case of BTV diminished during the infection.
EXPERIMENTAL PROCEDURES
Cell lines and viruses—BSR cells (BHK-21 subclone) (ATCC®
CCL10™), HeLa cells (HeLa, ATCC® CCL-2™) and sheep PT cells
(ovine-derived kidney cells, ATCC® Number: CRL-1633™) were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-
Aldrich) Equine dermal (E. Derm) cells (NBL-6, ATCC CCL-57) were
cultured in Eagle minimum essential medium (MEM; Sigma). Both
media were supplemented with 10% (v/v) fetal bovine serum (FBS;
Invitrogen), 100 U of penicillin/ml, and 100 g of streptomycin/ml
(Sigma-Aldrich) and MEM Non-Essential Amino Acids (Gibco). BTV
serotype 1 (BTV-1) and AHSV serotype 1 (AHSV-1) stock was ob-
tained by infecting BSR cells at a low multiplicity of infection (MOI)
and harvested when a 100% cytopathic effect was evident. Virus
stocks were stored at 4 °C.
Pharmacological Reagents—H-89 (PKA inhibitor) (tlrl-h89, Invivo-
gen), Dibutyryl-cAMP (PKA activator) (sc-201567, Santa Cruz Bio-
technology, Inc), Akt Inhibitor VIII (AKT inhibitor) (124018–1MG,
Merck). All reagents were used at the concentrations specified.
Infection Techniques—For studies of viral infection, HeLa, PT and
E. derm cell monolayers were washed with FBS-free medium and
infected with BTV or AHSV at an MOI of 5. Virus adsorptions were
carried out for 30 min at 4 °C, followed by incubation at 37 °C in
growth medium (in the presence or absence of pharmacological
activator or inhibitors) for 12, 18, 24, and 36 h.
Plaque Assays—BSR cells were grown in 6 well plates and infected
with virus recovered from previously infected cells that had been
treated with a carrier medium, activator or inhibitors, as described
above. Following adsorption for 30 min at 4 °C, cells were incubated
at 37 °C in growth medium for 1 h. Growth medium was removed and
replaced by 0.6% Avicel (FMC BioPolymer) overlay medium (Eagle’s
MEM containing L-glutamine, 10% FBS and antibiotics). Cells were
incubated at 37 °C for 72 h before being fixed with 4% paraformal-
dehyde and subsequently stained with crystal violet. Titers were
expressed as plaque forming units per ml (Pfu/ml).
Western Blot Analysis—SDS-PAGE gels were transferred via a
semi-dry blotter to PVDF transfer membranes and blocked for 4 h
with TBS-T containing 10% (w/v) milk powder. Primary antibodies
that were used for the detection of BTV included NS2 (Guinea pig
anti-NS2 serum), VP5 (Guinea pig anti-VP5 serum), NS1 (Rabbit anti-
NS1) and GAPDH (rabbit anti-GAPDH (ab9485; Abcam) as a host
cell marker. AHSV NS2 protein was detected using a polyvalent
serum (horse-derived). Further, rabbit anti-Phospho-PKA substrate
(RRXS/T) (100G7E) (9624, Cell Signaling) and rabbit anti-Phospho-
AKT substrate RXRXXS/T) (110B7E) (9614, Cell Signaling) were used
to detect phosphorylated substrates. Primary antibodies were added
to membranes and incubated overnight at 4 °C. Secondary antibod-
ies (IgG, 1:10,000) were alkaline phosphatase-conjugated goat anti-
guinea pig immunoglobulin G (Sigma-Aldrich, A5062), goat anti-rabbit
(Sigma-Aldrich, A0418) and rabbit-anti-horse (Sigma-Aldrich, A6063).
SILAC Experiment—HeLa cells were SILAC labeled using SILAC
medium (R0K0, R6K4, R10K8) from Dundee Cell Products for eight
cell passages. Cells were infected with an MOI of 5. At 12 h and 18 h
post infection (h.p.i), cells were washed with PBS and lysed using
lysis buffer (8 M Urea, 75 mM NaCl, 50 mM Tris, pH 8.2, Protease
inhibitor mixture (Promega), 1 mM NaF, 1 mM Beta-glycerophosphate,
1 mM orthovanadate, 10 mM sodium pyrophosphate and 1 mM PMSF).
Cellular debris was spun down and lysates combined in a 1:1:1 ratio
prior to and subjected to phosphopeptide enrichment and analysis via
mass spectrometry (University of Bristol).
LC-MS/MS and Sample Preparation—SILAC pools were reduced
(20 mM TCEP for 1 h at 55 °C), alkylated (35 mM iodoacetamide for
30min at room temperature) and proteins precipitated using 6 vol-
umes of acetone (15 h, 20 °C). Precipitated proteins were resus-
pended in 100 mM TEAB to which 2.5% (w/w) trypsin was added and
the samples incubated overnight at 37 °C. Following digestion, the
samples were resuspended in 5% formic acid and desalted using
SepPak cartridges according to the manufacturer’s instructions (Wa-
ters, Milford, MA). 1 mg of Eluate from the SepPak cartridge was first
desiccated and then resuspended for either TiO2-based or Fe-NTA-
based phosphopeptide enrichment (0.5 mg was used for each) ac-
cording to the manufacturer’s instructions (Pierce). Enriched phos-
phopeptides were then fractionated using a Dionex Ultimate 3000
nanoHPLC system in line with an LTQ-Orbitrap Velos mass spectrom-
eter (Thermo Scientific). In brief, peptides in 1% (v/v) formic acid were
injected onto an Acclaim PepMap C18 nano-trap column (Thermo
Scientific). After washing with 0.5% (v/v) acetonitrile 0.1% (v/v) formic
acid peptides were resolved on a 250 mm  75 m Acclaim PepMap
C18 reverse phase analytical column (Thermo Scientific) over a 150
min organic gradient, using 7 gradient segments (1–6% solvent B
over 1min., 6–15% B over 58min., 15–32%B over 58min., 32–40%B
over 5min., 40–90%B over 1min., held at 90%B for 6min and then
reduced to 1%B over 1min, with a flow rate of 300 nl/min. Solvent A
was 0.1% formic acid and Solvent B was aqueous 80% acetonitrile in
0.1% formic acid. Peptides were ionized by nano-electrospray ioni-
zation at 2.1 kV using an emitter with an internal diameter of 30 m
(Thermo Scientific) and a capillary temperature of 250 °C. Tandem
mass spectra were acquired using an LTQ- Orbitrap Velos mass
spectrometer controlled by Xcalibur 2.1 software (Thermo Scientific)
and operated in data-dependent acquisition mode. The Orbitrap was
set to analyze the survey scans at 60,000 resolution (atm/z 400) in the
mass range m/z 300 to 1800 and the top 12 multiply charged ions in
each duty cycle selected for MS/MS in the LTQ linear ion trap. Charge
state filtering, where unassigned precursor ions were not selected for
fragmentation, and dynamic exclusion (repeat count, 1; repeat dura-
tion, 30 s; exclusion list size, 500) were used. Fragmentation condi-
tions in the LTQ were as follows: normalized collision energy, 35%;
activation q, 0.25; activation time 10ms; and minimum ion selection
intensity, 500 counts. Multistage activation was enabled with neutral
loss masses of 32.7, 49, and 98.
Data Analysis—The raw data files were processed and quantified
using Maxquant v1.5.7.4 (21) and searched against the Uniprot Hu-
man database (70,550 entries, downloaded September 19th, 2016)
plus a custom fasta file generated in-house containing the BTV pro-
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tein sequences (South African reference strain, Genbank accession
numbers FJ969719-FJ969728) which is included as part of PRIDE
submission PXD005550. Precursor mass tolerance was set at
4.5ppm, and MS/MS tolerance was set at 0.5Da. Search criteria
included carbaminomethylation of cysteine as a fixed modification.
Oxidation of methionine, N-terminal acetylation, and STY phos-
phorylation were selected as variable modifications. Quantification
was based on Light (Arg 0, Lys 0), Medium (Arg 6, Lys 4), and Heavy
(Arg 10, Lys 8) SILAC labels. Searches were performed with full tryptic
digestion, a minimum peptide length of 7 amino acids, and a maxi-
mum of 2 missed cleavages were allowed. The reverse database
search option was enabled and the maximum false discovery rate for
both peptide and protein identifications was set to 0.01. Quantitation
was performed using a mass precision of 2 ppm and the requantify
option in Maxquant was enabled. The full Maxquant output is pro-
vided as part of PRIDE submission PXD005550 permitting viewing of
annotated spectra in Maxquant v1.5.7.4. Downstream analysis
was accomplished in the Perseus software (22). In all cases, contam-
inants and reverse database hits were removed. Downstream phos-
phosite analysis was restricted to those with a localization probability
of 0.75 and a score difference of over 5 (also referred to as class I
phosphosites). Protein, peptides or site ratios were converted to log2
and the mean log2 ratios across the three replicates were calculated.
Only data obtained for at least two of the three biological replicates
were used for further analysis, this would exclude a peptide identified
in both the TiO2 and Fe-NTA samples from an individual biological
replicate.
Weblogo (23) was used to produce sequence logos looking at
phosphorylation site motifs. To identify significantly altered phos-
phorylation patterns, phosphorylation sites (supplemental Table S3)
which showed a significant alteration in the abundance by t test (p 
0.05) were analyzed using the Motif-X software (24). The settings used
were width 13, Occ 20, and central S/T. Phosphotyrosine enrichment
was not investigated using motif-x because of the low numbers of
identified phosphosites. Motif-X analysis is shown in supplemental
Table S6.
Gene ontology analysis was performed using STRING version 10.5
(https://string-db.org) (25) using phosphoproteins identified as regu-
lated based on their inclusion of at least one regulated phosphosite.
These data are listed in supplemental Table S5.
Phoxtrack (26) was used to test for enrichment of activated or
inhibited kinases in the sample. Phosphosite windows ( 6 amino
acids) and mean log2 ratios were uploaded to the software. Phoxtrack
was set to require a minimum of two phosphosites per kinase, and
10,000 permutations. The human PhosphoSitePlus, SWISS-Prot,
HPRD and Phospho.ELM were selected as the databases for screen-
ing. Phoxtrack kinase and substrate analysis are shown in supple-
mental Table S7.
Experimental Design and Statistical Rationale—The phosphopro-
teomic experiment was performed with 3 independent biological rep-
licates, with each replicate divided into two aliquots for parallel en-
richment of phosphopeptides using either TiO2 or FeNTA. These were
performed using SILAC-labeled cells, allowing comparison of mock
infected cells (12h) with BTV infected cells at either 12 h.p.i or 18 h.p.i.
Label-switching was performed in one replicate (replicate 2) to control
for any impact of the SILAC labeling on the cell culture. Mass spec-
trometry was performed on infected human HeLa cells, rather than
the more usual ovine host cells, because of superior annotation and
analysis support for human proteomic data. For stringency, down-
stream analysis was restricted to high-confidence class I phospho-
sites, and both phosphoproteins and phosphosites had to be identi-
fied in at least 2/3 experiments to be used for downstream analysis.
Analysis was performed as described in data analysis.
Quantification of Protein Levels and Phosphorylation by Densitom-
etry—Immunoblots were scanned and analyzed via semi-quantified
densitometry, using ImageJ, available through the National Institutes
of Health.
RESULTS
Phosphoproteomic Analysis of BTV Infected HeLa Cells
Reveals Changes in Cellular Protein Phosphorylation Pro-
files—HeLa cells were labeled with light (R0K0), medium
(R6K4), and heavy (R10K8) amino acids. Cells were mock
infected (R0K0) and infected (R6K4 and R10K8) with BTV
(MOI  5) and harvested at either 12 h.p.i or 18 h.p.i. Suc-
cessfully infected cell lysates within each replicate experiment
were combined, trypsin digested and enriched for phospho-
peptides, followed by LC-MS/MS (Fig. 1A). Lysates from three
replicate experiments were analyzed on SDS-PAGE gels and
Western blots carried out to confirm the successful infection
of cells. HeLa cells infected with BTV (R6K4 and R10K8)
demonstrated the presence of viral proteins, including the
structural proteins VP2, VP5, VP7, and the nonstructural pro-
tein NS1 and NS2, confirming successful viral entry and rep-
lication. Viral protein concentrations increased concurrently to
the temporal progression of the infection between 12 h.p.i and
18 h.p.i (Fig. 1B).
Phosphopeptide enrichment was carried out using com-
plementary Fe-NTA and Ti02 enrichment procedures. The
phosphoproteins, phosphopeptides, and high confidence
phosphosites identified by this analysis are detailed in
supplemental Tables S1–S3 respectively. Summary data is
presented in Table I. Of the 4823 peptides identified, 1384
phosphopeptides were identified, corresponding to 29% of
the total. 704 (50.9%) of these phosphopeptides were com-
mon to both enrichment methods (supplemental Fig. S1B).
Two hundred peptides were unique to the Fe-NTA enrich-
ment, whereas TiO2 enrichment identified a further 480
phosphopeptides, which had not been identified following
Fe-NTA enrichment. The identified peptides corresponded
to 1599 proteins, of which 598 represented phospho-
proteins (supplemental Table S1). Experimental replicates
showed high correlation between replicates (supplemental
Fig. S2) with Pearsons correlation coefficients in the range
0.786–0.835. No significant difference in enrichment of single
or multiple phosphorylated peptides was observed between
the two enrichment methods (supplemental Fig. S1C and
S1D). Overall, 70% of the phosphopeptides had a single
phosphorylated residue, 25% had two, and the remainder
three or four (Fig. 1C). The phosphosites could be divided into
89% Ser, 9% Thr, and 2% Tyr phosphorylation sites (Fig. 1D)
which is comparable with other global phosphoproteomic
studies (27). Phosphosites were further processed to ensure
only those with a high localization probability and those iden-
tified in multiple biological repeats were used for downstream
kinase analysis. These 922 high-confidence phosphosites are
detailed in supplemental Table S3. Although a majority of viral
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proteins were detected confirming Western blotting data (Fig.
1B) of a successful infection, no phosphorylated viral peptides
were observed in this analysis. As expected, only a small
subset of phosphosites show differential regulation upon BTV
infection (supplemental Fig. S3), with the majority showing
negligible change. Full details on the relative levels of individ-
ual phosphosites are shown in supplemental Table S3. sup-
plemental Table S4 details all the phosphoproteins, phospho-
peptides, and phosphosites that were considered to be
significantly regulated by BTV infection (t test, p  0.05).
Gene ontology (GO) analysis of phosphoproteins signifi-
cantly regulated by BTV infection was performed using the
STRING database (supplemental Table S5). Analysis revealed
most phosphoproteins participating in biological processes
involving cellular or RNA metabolism. However, cell cycle
processes (FDR 6.22E-08) and proteins involved in viral pro-
cesses (1.76E-07) were also identified. Previous studies on
BTV infection revealed cell cycle disregulation so these data
are consistent with prior observations (28). GO Molecular
functions of regulated phosphoproteins showed an over-
representation of RNA or nucleic-acid binding proteins, and
analysis of cellular localization (GO Cellular component)
suggested nuclear proteins dominated. KEGG analysis
identified only a single hit, with spliceosome components
overrepresented.
Motif analysis using sequence logos of the 922 phos-
phorylation sites identified within the dataset is presented in
Fig. 2. Phospho-serine sites dominate with 89% of the iden-
tified sites, followed by phospho-threonine (9%) and phos-
pho-tyrosine (2%). The phospho-serine sites can be further
divided into proline-directed (46%), acidophilic (28%), baso-
philic (23%) and other sites (19%) though there can be some
cross-over between these categories. The proportions ob-
served were consistent with previous studies using this ap-
proach (29). Proline-directed kinases include MAPK, CDK,
FIG. 1. Experimental design and validation of infection with BTV. A, A schematic representation of the phosphoproteomic experimental
design is shown. The use of medium and heavy media for the 12h and 18h samples respectively was observed for experiments 1 and 3, and
in experiment 2 the media was switched to control for potential impacts on cell growth or infection. B, Infection conditions within the various
samples submitted for LC-MS/MS analysis were confirmed by Western blotting against viral antigens indicated on the left. Cellular GAPDH was
used as a loading control. C, The number (percentage of the table) and D, percentage identity of phosphorylation sites within the total
phosphoproteomic dataset obtained is shown.
TABLE I.
Summary data
A summary of the various numbers of proteins, peptides and phos-
phosites identified in this manuscript. Numbers exclude contami-
nants, the proteins and peptides listed are nonredundant across the
three experiments, and to be classed as a high confident phospho-
site, a site needed to be identified with a localization score of 0.75
and in at least 2 of the 3 experiments.
Phosphoproteins (598)
Phosphoproteins with 1 regulated
phosphosites
48.5% (290)
12h/Mock 34.9% (209)
18h/Mock 36.6% (219)
18h/12h 11.7% (70)
Phosphopeptides (1384)
Regulated phosphopeptides 35.4% (490)
12h/Mock 23.4% (324)
18h/Mock 23.8% (330)
18h/12h 6.7% (93)
High confidence phosphosites (922)
Regulated phosphosites 53.5% (493)
12h/Mock 35.2% (325)
18h/Mock 36.0% (332)
18h/12h 9.9% (91)
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ERK, JNK, and GSK. The acidophilic motif identified is con-
sistent with CK2 substrates or polo-like kinases (30). Baso-
philic motifs, including an arginine at the 3 position, are
targets of a range of kinases including PKA, Akt, and AMPK
(31, 32). When investigating proteins showing significant al-
terations in their abundance (t test, p 0.05), proline-directed
motifs dominate, which is consistent with their over-represen-
tation within the data set (supplemental Fig. S4A–S4C). How-
ever, when the later 18 h time point is compared with the 12 h
time point, it is clear that some other motifs are increasing in
abundance with the appearance of arginine at the3 position
in the sequence logo suggesting regulation of basophilic mo-
tifs (supplemental Fig. S4C). Although information can be
gained by sequence logos in this manner, they do lack detail
on minor variants, requiring more detailed investigation.
To elucidate the kinases involved, we used two comple-
mentary approaches, X-track motif analysis to identify signif-
icantly over-represented motifs (24) and Phoxtrack (PHO-
sphosite-X-TRacing Analysis of Causal Kinases) (26). The
Phoxtrack software uses non-parametric statistics to deter-
mine whether defined kinase specific sets of phosphosites,
derived from a selection of public databases, show significant
and concordant differences in their abundance between bio-
logical samples.
Motif-X was used to identify sequence motifs from the
phosphosite data based on a 6 to 6 sequence window
around the phosphorylated residue at position 0. T-tests were
performed on the high confidence phosphosites identified
(supplemental Table S3) and those showing significantly al-
tered abundance (p  0.05) were used for motif analysis
(supplemental Table S6). Motif analysis was also performed
on the total phosphosite dataset from supplemental Table S3
to identify the full range of motifs enriched within this exper-
iment. No threonine motifs were identified as significantly
regulated by the software, most likely because of the low
proportion of phosphothreonine peptides in the dataset. Ty-
rosine motifs were omitted from the analysis for this reason.
However, several serine-centered motifs were identified as
regulated by BTV at both 12 h.p.i and 18 h.p.i, which corre-
sponded to known phosphorylation motifs. Akt-based motifs
(RxxS) showed regulation by BTV, as did CK (SDxE), GSK3
(SxxxSP) and ERK1/2 (SP). Except for GSK3, these kinases
have been shown to have a role in BTV infection previously
(14, 33) suggesting the approach has successfully confirmed
previous results, as well as identifying a potentially novel
kinase.
For a more sensitive approach, we applied Phoxtrack to
investigate the high-confidence phosphosites (supplemental
Table S3) to identify both kinases and kinase substrates ex-
hibiting significant enrichment (Fig. 2). (supplemental Table S7
shows the complete list of data obtained. Note that as the
different databases searched by phoxtrack use different no-
menclature, the same kinase can be identified from different
databases or under different names. Prospective novel ki-
nases that were identified included p21-activated protein ki-
nase 2 (PAK2), Protein kinase C delta type (PKCD), PAS
Domain Containing Serine/Threonine Kinase (PASK), Death-
associated protein kinase 1 (DAPK1), Ribosomal Protein S6
Kinase A1 and 3 (RPS6KA1 and 3), Protein Kinase A (PKA)
and Polo Like Kinase 3 (PLK3) (Table II).
FIG. 2. Identification of sequence motifs within the phosphoproteome of BTV-infected cells. The 922 high confidence phosphosites
(see supplemental Table S3) were analyzed with sequence logos prepared using the weblogo software. These could be further divided into
phospho(S/T/Y) sites and the phospho(S) sites divided down further still into proline-directed, acidophilic, basophilic or other sites.
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TABLE II.
Kinase regulation during BTV infection
The Phoxtrack software was used to identify significantly regulated kinases from the total set of phosphosite motifs identified. The software
identifies the same kinase multiple times if this is found in several databases, here only the highest scoring hit is shown. The full data set is
given in Table S7. The heading details the kinase identified, the database used for identification, the number of phosphosites used, normalized
enrichment value, p value, and where a report of kinase regulation by BTV has previously been made, the reference.
Kinase Database No. of phosphosites NEV p value Reference
12 h Upregulated
PAK2 HPRD 4 2.32 0
P70S6K PSP 6 2.3 6.00E-04 (20)
CDK1 PSP 20 1.99 0.005
PKCD PSP 4 1.93 0.0046
PASK Swiss 2 1.78 0.0022
DAPK1 Swiss 2 1.77 0.0034
RPS6KA3 Swiss 2 1.77 0.0034
RPS6KA1 Swiss 2 1.77 0.002
CK Swiss 2 1.58 0.0387 (14)
PRKCA (PKA) HPRD 2 1.56 0.0489
12 h Downregulated
TESK2 HPRD 2 1.84 0
LIMK1 PSP 2 1.83 4.00E-04
LIMK2 PSP 2 1.83 0
P38-ALPHA (MAPK14) PSP 4 1.76 0.0166 (66, 67)
JNK2 PSP 3 1.56 0.0471 (67)
18 h Upregulated
P70S6K PSP 6 2.55 2.00E-04 (20)
CDK1 PSP 20 2.5 0.001
PAK2 HPRD 4 2.43 0
RSK_GROUP (RPS6K) PELM 4 2.18 6.00E-04
PKCD PSP 4 1.93 0.0054
CDK_GROUP PELM 2 1.84 0
PASK Swiss 2 1.77 0.0024
PKACA (PKA) PSP 6 1.77 0.0169
DAPK1 Swiss 2 1.77 0.0036
18 h Downregulated
PLK3 PSP 3 2.08 4.00E-04
JNK2 PSP 3 2.07 6.00E-04 (67)
MAPK14 Swiss 3 2.06 4.00E-04
ERK2 PSP 3 1.98 0.003 (20)
MAP2K_GROUP PELM 2 1.82 0.001
RET PSP 2 1.82 6.00E-04
MAPK11 Swiss 2 1.74 0.006
MAPK8 (JNK1) PELM 2 1.73 0.0083 (67)
ERK1 PSP 6 1.69 0.0273 (20)
18 h over 12 h Upregulated
P90RSK PSP 5 2.15 0.0014
PAK2 HPRD 4 1.94 0.0058
LIMK2 PSP 2 1.84 4.00E-04
TESK2 HPRD 2 1.83 2.00E-04
LIMK1 PSP 2 1.82 0
P70S6K PSP 6 1.81 0.0138 (20)
CDK1 PSP 20 1.76 0.0208
PDK1 PSP 3 1.58 0.0455
PAK1 PELM 2 1.57 0.0455
18 h over 12 h
Downregulated
MAPK14 Swiss 3 2.15 0 (67)
RET PSP 2 1.84 0
ERK1 PSP 6 1.84 0.0113 (20)
MAP2K_GROUP PELM 2 1.82 0
MAPK9 (JNK2) HPRD 2 1.8 0.001 (67)
MAPK11 Swiss 2 1.79 6.00E-04
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At both 12 h.p.i and 18 h.p.i, phosphorylated ribosomal
protein S6 kinase beta-1 (p70S6 kinase), PKA, Protein Kinase
C (PKC) and CDK1/2 substrates were enriched. MAPK14
(P38-MAPK) and JNK2 substrates were reduced in their abun-
dance (Table II). Many of the kinase substrates at 18 h showed
an increase on their 12 h phenotype such as p70S6K and
CDK1. In other cases, several kinase substrates only showed
significant differences at 18 h.p.i such as decreased ERK1/2
and PLK3. Notably several kinases show diminished activity
at 12 h.p.i compared with mock, but activity appears restored
by 18 h.p.i. LIMK1 and 2, and TESK, show this pattern. One
weakness of the phoxtrack approach is that only a single
abundance value can be applied. Here we used average fold
change from a minimum of 2 of our 3 experiments. However,
this does mean that data on variation between experiments is
lost and not considered when determining kinase enrichment
with this method. Between the phoxtrack and motif-x analy-
ses, most of the previously described impacts of BTV infec-
tion on kinase activity have been recapitulated in this dataset,
and prospective novel kinases identified.
Depletion of PKA Phosphorylated Substrates Following In-
fection with BTV Reduces Viral Replication, Whereas Enrich-
ment of PKA Phosphorylated Substrates Enhances Viral Rep-
lication—Because our phosphoproteomic analysis identified
PKA, also known as cAMP-dependent protein kinase, as a
novel kinase active during BTV infection, we wanted to vali-
date and assess its role during BTV replication. To this end,
we used the PKA inhibitor H89 (34) and the PKA activator
Dibutyryl-cAMP (35) to explore the effects of PKA inhibition
and activation on BTV replication. Although HeLa cells sup-
port BTV replication successfully and were chosen for the
initial phosphoproteomic characterization of BTV infection,
because of the superior annotation of the human proteome
and availability of analysis tools (Fig. 1), it was necessary to
complement our analysis by carrying out replicate experi-
ments using a natural host cell line, such as sheep derived PT
cells.
To determine the effects of inhibition or activation of PKA
activity on BTV protein levels, the lysates of HeLa and sheep
PT cells infected with BTV were analyzed. Cells were treated
1 h.p.i with DMSO, 40 M H89, or 1 mM Dibutyryl-cAMP and
harvested at 12 h.p.i and 18 h.p.i. for analysis by Western
blotting. Representative Western blots are shown for 12 h.p.i
(supplemental Fig. S5A) and 18 h.p.i. (supplemental Fig. S5B).
Quantification of Western blots via densitometry for sam-
ples collected 12 h.p.i (Fig. 3A) validated the effects of H89
and Dibutyryl-cAMP on the levels of phosphorylated PKA
substrates normalized to host cell GAPDH levels in mock, or
noninfected, HeLa or sheep PT cells. Mock infected cells
treated with the H89 inhibitor showed a significant decrease in
phosphorylated PKA substrates compared with DMSO-only
treated cells. Phosphorylated PKA substrates decreased by
	43% ( 5%) in HeLa cells and by	40% ( 6%) in sheep PT
cells (Fig. 3A). Concurrently, cells treated with the Dibutyryl-
cAMP activator showed a significant increase in phosphoryl-
ated PKA substrates compared with DMSO-only treated cells.
Phosphorylated PKA substrates increased by 	14% ( 4%)
in HeLa cells and by 	30% ( 10%) in sheep PT cells
(Fig. 3A).
At 12 h.p.i there is no significant increase of phosphorylated
PKA substrates in infected HeLa or sheep PT cells, when
compared with mock infected cells (Fig. 3A). This observation
was consistent with our phosphoproteome data (supplemen-
tal Table S1–S5). However, BTV infected cells treated with the
H89 inhibitor showed significant decreases in phosphorylated
PKA substrates compared with DMSO treated cells. Phos-
phorylated PKA substrates decreased by 	51% ( 8%) in
HeLa cells and by 	44% ( 6%) in sheep PT cells (Fig. 3A).
Similarly, to mock infected cells, BTV infected cells treated
with the Dibutyryl-cAMP activator showed a significant in-
crease in phosphorylated PKA substrates compared with
DMSO-only treated cells, increasing by	26% ( 5%) in HeLa
cells and by 	33% ( 4%) in sheep PT cells (Fig. 3A).
In addition to these changes, we also observed changes in
viral protein levels, including NS1 and NS2. When NS2 protein
levels were normalized to host cell GAPDH levels via densi-
tometry in replicate experiments, H89 treatment significantly
decreased NS2 protein levels compared with the DMSO con-
trol (Fig. 3A). In HeLa cells, the viral NS2 protein levels de-
creased by	60% ( 11%) and by	64% ( 9%) in sheep PT
cells following treatment of cells with the PKA inhibitor (Fig.
3A). Conversely, in cells treated with Dibutyryl-cAMP, the viral
NS2 protein levels increased by 	24% ( 12%) in HeLa cells
and by 	15% ( 6%) in sheep PT cells (Fig. 3A).
In parallel, to determine whether PKA inhibition also af-
fected infectious virus production, virus titers of replicate
lysates of infected cells were determined by plaque assays. At
12 h.p.i, the titer of the DMSO-only control was 	3  104
Pfu/ml, which decreased to 	7.5  102 Pfu/ml in the pres-
ence of 40 M H89 and was	2.7 104 Pfu/ml in the presence
of 1 mM Dibutyryl-cAMP (supplemental Fig. S10A).
At 18 h.p.i there is a significant increase of phosphorylated
PKA substrates in infected HeLa and sheep PT cells when
compared with mock infected cells (Fig. 3B), this observation
agrees with the phosphoproteome data obtained (supple-
mental Table S3–S5). Like the data at 12 h.p.i., samples
collected at 18 h.p.i (Fig. 3B) showed the effects of H89 and
Dibutyryl-cAMP on the levels of phosphorylated PKA sub-
strates normalized to host cell GAPDH levels in mock, or
non-infected, HeLa or sheep PT cells. Mock infected cells
treated with the H89 inhibitor showed a significant decrease in
phosphorylated PKA substrates compared with DMSO-only
treated cells, decreasing by 	39% ( 12%) in HeLa cells and
by 	38% ( 17%) in sheep PT cells (Fig. 3B). Further, cells
treated with the Dibutyryl-cAMP activator showed a signifi-
cant increase in phosphorylated PKA substrates compared
with DMSO-only treated cells, increasing by 	26% ( 8%) in
HeLa cells and by 	24% ( 16%) in sheep PT cells (Fig. 3B).
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BTV infection resulted in an increase of phosphorylated
PKA substrates in HeLa cells by 	18% ( 11%), and by
	30% ( 15%) in sheep PT cells (Fig. 3B). Like the changes
observed at 12 h.p.i, BTV infected cells treated with the H89
inhibitor showed significant decreases in phosphorylated PKA
substrates compared with mock infected cells, decreasing by
	36% ( 16%) in HeLa cells and by 	51% ( 19%) in sheep
PT cells (Fig. 3B). Like mock infected cells, BTV infected cells
treated with the Dibutyryl-cAMP activator showed a signifi-
cant increase in phosphorylated PKA substrates compared
with DMSO-only treated cells, increasing by 	45% ( 21%)
in HeLa cells and by 	37% ( 17%) in sheep PT cells (Fig.
3B). Following treatment with the PKA inhibitor, NS2 protein
levels decreased significantly by	52% ( 14%) in HeLa cells
and by	40% ( 17%) in sheep PT cells (Fig. 3B). In contrast,
in cells treated with Dibutyryl-cAMP, the viral NS2 protein
levels increased by 	28% ( 15%) in HeLa cells and by
	32% ( 15%) in sheep PT cells (Fig. 3B). Like 12 h.p.i, at
18 h.p.i, we also observed a decrease in virus titer when
assaying replicate lysates via plaque assay. The titer of the
DMSO-only control was	2 105 Pfu/ml, decreasing to	2
103 Pfu/ml at 40 M H89 and was	2.7  104 Pfu/ml in the
presence of 1 mM Dibutyryl-cAMP (supplemental Fig. S10B).
Decreases or Increases in PKA-dependent Phosphorylated
Substrate Levels Prior To Infection Do Not Affect BTV Replica-
tion—Because our data showed that PKA inhibition decreases
BTV replication and PKA activation increased BTV replication
(Fig 3A and 3B) following infection, we wanted to examine
whether depletion or enrichment of PKA phosphorylated sub-
strates prior to virus entry could further decrease or increase
virus replication by influencing virus entry (Fig. 4). An aspect that
had previously been documented for HCV (17). Therefore, HeLa
and sheep PT cells were pre-treated with DMSO, 40 M H89 or
1 mM Dibutyryl-cAMP for 1 h prior to infection. Cell lysates were
subsequently analyzed by Western blot analysis and represent-
ative Western blots are shown (supplemental Fig. S6).
FIG. 3. Inhibition of PKA reduces BTV replication whereas further stimulation of PKA enhances BTV replication. HeLa and sheep PT
cells infected with BTV1 (MOI  5) were treated 1 h.p.i with 40 M H89 or 1 mM Dibutyryl-cAMP and harvested 12 h.p.i (A) and 18 h.p.i (B).
Mock infected and DMSO treated cells were included as controls. Samples were analyzed by Western blot and densitometry analysis of
phosphorylated-PKA substrates and NS2. Results are expressed as the relative protein levels as indicated on the left. Error bars represent the
S.D. values of stimulations from three independent experiments. A star (*) denotes a significant difference from control (p  0.05).
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Densitometry quantification of Western blots confirmed that
at the time of infection (0 h), phosphorylated PKA substrate
levels had significantly decreased following treatment with
H89 by 	58% ( 15%) in HeLa cells and by 	40% ( 20%)
in sheep PT cells. Cells treated with the Dibutyryl-cAMP ac-
tivator showed a significant increase in phosphorylated PKA
substrates compared with DMSO-only treated cells, increas-
ing by 	40% ( 16%) in HeLa cells and by 	31% ( 9%) in
sheep PT cells (Fig. 4). These data confirmed the respective
depletion and enrichment of phosphorylated substrate prior
to infection (Fig. 4).
At 18 h.p.i there is a significant increase of phosphorylated
PKA substrates in infected HeLa and sheep PT cells when
compared with mock infected cells (Fig. 4). Phosphorylated
PKA substrates in infected HeLa cells increased by 	30% (
10%) and by 	32% ( 19%) in sheep PT cells (Fig. 4). BTV
infected cells treated with the H89 inhibitor showed significant
decreases in phosphorylated PKA substrates, decreasing by
	51% ( 22%) in HeLa cells, and by	36% ( 12%) in sheep
PT cells (Fig. 4). Cells treated with the Dibutyryl-cAMP acti-
vator showed a significant increase in phosphorylated PKA
substrates compared with DMSO-only treated cells, increas-
ing by 	38% ( 8%) in HeLa cells and by 	29% ( 1%) in
sheep PT cells (Fig. 4). Following treatment with the PKA
inhibitor prior to infection, NS2 protein levels decreased sig-
nificantly by 	43% ( 17%) in HeLa cells and by 	37% (
12%) in sheep PT cells (Fig. 4). Conversely, in cells treated
with Dibutyryl-cAMP, the viral NS2 protein levels increased by
	14% ( 4%) in HeLa cells and by 	23% ( 12%) in sheep
PT cells (Fig. 4).
Overall, these data from post (Fig. 3) and pretreated (Fig. 4)
samples suggest that depleting or enriching cells of phos-
phorylated PKA substrates prior to infection provides no ef-
fect on the inhibition or enhancement of viral replication. This
may also suggest that these phosphorylated PKA substrate
are not essential during viral cell entry.
Depletion of PKA Phosphorylated Substrates Following In-
fection with AHSV Reduces Viral Replication, Although En-
richment of PKA Phosphorylated Substrates Enhances Viral
Replication—To investigate whether the activation of PKA is
a common phenomenon among orbiviruses, we conducted
similar studies using African horse sickness virus (AHSV).
HeLa cells that support AHSV infection and natural host cells,
E. Derm cells, an equid derived dermal cell line, were infected
with AHSV in parallel. Cells were treated 1 h.p.i with DMSO,
40 M H89 or 1 mM Dibutyryl-cAMP and harvested 18 h.p.i.
Cell lysates were analyzed by Western blot (supplemental Fig.
S7A).
Quantification of Western blots by densitometry validated
the effects of H89 and Dibutyryl-cAMP on the levels of phos-
phorylated PKA substrates normalized to host cell GAPDH
levels in mock, or non-infected, HeLa or E. Derm cells (Fig 5A).
Mock infected cells treated with the H89 inhibitor showed a
significant decrease in phosphorylated PKA substrates com-
pared with DMSO-only treated cells, decreasing by 	41% (
6%) in HeLa cells and by	49% ( 8%) in E. Derm cells. Cells
treated with the Dibutyryl-cAMP activator showed a signifi-
cant increase in phosphorylated PKA substrates compared
with DMSO-only treated cells, increasing by 	57% ( 24%)
in HeLa cells and by 	36% ( 13%) in E. Derm cells.
AHSV infection resulted in an increase of phosphorylated
PKA substrates in HeLa cells by 	29% ( 12%), and by
	36% ( 21%) in E. Derm cells (Fig. 5A). Infected cells
treated with the H89 inhibitor showed significant decreases in
phosphorylated PKA substrates compared with mock in-
fected cells, decreasing by 	45% ( 13%) in HeLa cells, and
FIG. 4. Decreases or increases in PKA-dependent phosphorylated substrate levels prior to infection do not affect BTV replication.
HeLa and sheep PT cells were treated with 40 M H89 or 1 mM Dibutyryl-cAMP for 1 h prior to infection with BTV1 (MOI  5) and harvested
18 h.p.i. As controls, mock infected and DMSO treated cells were included. Samples were analyzed by Western blot densitometry analysis of
phosphorylated-PKA substrates and NS2 are shown. Results are expressed as the percentage of protein levels as indicated. Error bars
represent the S.D. values of stimulations from three independent experiments. A star (*) denotes a significant difference from control (p 0.05).
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by 	30% ( 15%) in E. Derm cells. Infected cells treated with
the Dibutyryl-cAMP activator showed a significant increase in
phosphorylated PKA substrates compared with DMSO-only
treated cells. Phosphorylated PKA substrates increased by
	50% ( 20%) in HeLa cells and by 	37% ( 13%) in E.
Derm cells. Following treatment with the PKA inhibitor, NS2
protein levels decreased significantly by 	58% ( 23%) in
HeLa cells and by 	57% ( 25%) in E. Derm cells. Whereas
in cells treated with Dibutyryl-cAMP, the viral NS2 protein
levels increased by 	33% ( 11%) in HeLa cells and by
	23% ( 7%) in E. Derm cells. These effects on viral repli-
cation were further validated by determining virus titer follow-
ing treatment with H89 and Dibutyryl-cAMP. 18 h.p.i, the titer
of the DMSO-only control was	5.5 105 Pfu/ml, decreasing
to 	2.1  103 Pfu/ml at 40 M H89 and was 	2.5  105
Pfu/ml in the presence of 1 mM Dibutyryl-cAMP (supplemental
Fig. S10C)
Changes in PKA-dependent phosphorylated substrate lev-
els prior to infection do not further impair or enhance AHSV
replication—To test whether our observations using BTV were
further comparable to AHSV, we examined whether depletion
or enrichment of PKA phosphorylated substrates prior to virus
entry could further decrease or increase virus replication (Fig.
5B). Therefore, HeLa and E. Derm cells were pretreated with
DMSO, 40 M H89 or 1 mM Dibutyryl-cAMP for 1 h prior to
infection and cell lysates were subsequently analyzed by
Western blot (supplemental Fig. S7B).
As expected at the time of infection (0 h), phosphorylated
PKA substrate levels had significantly decreased following a
1 h treatment with H89 by 	56% ( 15%) in HeLa cells and
FIG. 5. Changes in the levels of PKA-dependent phosphorylated substrates post or prior to infection do not further affect AHSV
replication. HeLa and Equine dermal (E. Derm) cells were treated 1 h.p.i (A) or for 1 h prior (B) to infection with AHSV1 (MOI  5) with 40
M H89 or 1 mM Dibutyryl-cAMP and harvested 18 h.p.i. As controls, mock infected and DMSO treated cells were included. Densitometry
analysis of phosphorylated-PKA substrates and NS2 are shown and the results presented as protein percentage, as indicated. Error bars
represent the S.D. values of stimulations from three independent experiments. A star (*) denotes a significant difference from control
(p  0.05).
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by	42% ( 17%) in E. Derm cells (Fig. 5B). Cells treated with
the Dibutyryl-cAMP activator showed a significant increase in
phosphorylated PKA substrates compared with DMSO-only
treated cells, increasing by	12% ( 2%) in HeLa cells and by
	26% ( 14%) in E. Derm cells. This confirmed the respec-
tive depletion and enrichment of phosphorylated substrate
prior to infection.
At 18 h.p.i there is a significant increase of phosphorylated
PKA substrates in infected HeLa and E. Derm cells when
compared with mock infected cells (Fig. 5B). Phosphorylated
PKA substrates in infected HeLa cells significantly increased
by 	27% ( 6%) and by 	36% ( 15%) in E. Derm cells.
AHSV infected cells treated with the H89 inhibitor showed
significant decreases in phosphorylated PKA substrates, de-
creasing by 	67% ( 13%) in HeLa cells, and by 	66% (
15%) in E. Derm cells (Fig. 5B). Concurrently, infected cells
treated with the Dibutyryl-cAMP activator showed a signifi-
cant increase in phosphorylated PKA substrates compared
with DMSO-only treated cells, increasing by 	39% ( 5%) in
HeLa cells and by 	40% (8%) in E. Derm cells. Following
treatment with the PKA inhibitor prior to infection, NS2 protein
levels decreased significantly by	75% ( 22%) in HeLa cells
and by 	75% ( 14%) in E. Derm cells. Cells treated with
Dibutyryl-cAMP, the viral NS2 protein levels increased by
	24% ( 8%) in HeLa cells and by	36% ( 14%) in E. Derm
cells (Fig. 5B). These data show that BTV and AHSV share a
similar response profile, this may suggest that these phos-
phorylated PKA substrate are not essential during viral cell
entry or early stages of virus replication.
Both BTV and AHSV Infection Increase Phosphorylation of
AKT Substrates—AKT pathway activity featured in our phos-
phoproteomics analysis, specifically via the Motif-X analysis
(supplemental Table S6), a pathway that was previous re-
ported to be involved in the BTV life-cycle (20), we thus
proceeded to use this for further validation of our phospho-
proteomics analysis. HeLa and sheep PT cells were infected
with BTV whereas HeLa and E. Derm cells were infected with
AHSV. Cell lysates were subsequently analyzed by Western
blot analysis and representative Western blots are shown for
BTV and AHSV. To determine the effects of inhibition of AKT
activity and to validate down-regulation of the AKT pathway,
cells were treated 1 h.p.i with 4 M Akt Inhibitor VIII (AKT VIII)
and harvested 18 h.p.i. (supplemental Fig. S8A and S8B).
Mock infected cells treated with the Akt Inhibitor VIII exhib-
ited a significant decrease in phosphorylated AKT substrates
compared with DMSO-only treated cells, decreasing by
	33% ( 2%) in HeLa cells and by	27% ( 8%) in sheep PT
cells (Fig. 6A). BTV infection resulted in an increase of phos-
phorylated AKT substrates in HeLa cells by 	57% ( 15%),
and by	52% ( 21%) in sheep PT cells (Fig. 6A). Akt Inhibitor
FIG. 6. BTV1 and AHSV1 increase AKT-dependent phosphorylated substrates. HeLa and sheep PT cells infected with BTV1 (MOI  5)
(A) or HeLa and Equine dermal (E. Derm) cells infected with AHSV1 (MOI  5) (B) were treated 1 h.p.i with 4 M Akt Inhibitor VIII (AKT VIII) and
harvested 18 h.p.i. Densitometry analysis of phosphorylated-AKT substrates and NS2 are presented as relative protein level percentage. Error
bars represent the S.D. values of stimulations from three independent experiments. A star (*) denotes a significant difference from control
(p  0.05).
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VIII treatment could significantly decrease the levels of phos-
phorylated AKT substrate in DMSO treated infected cells,
decreasing by 	55% ( 19%) in HeLa cells and by 	52% (
10%) in sheep PT cells. Further, NS2 protein levels decreased
by 	19% ( 6%) in HeLa cells and by 	18% ( 11%) in
sheep PT cells (Fig. 6A). However, we did not observe any
concomitant decrease in virus titer in the presence of the AKT
inhibitor (supplemental Fig. S10D).
Similarly, we then proceeded to determine whether AHSV
infections would elicit a similar response. As we had done for
BTV, we validated the effects of Akt Inhibitor VIII on the levels
of phosphorylated AKT substrates normalized to host cell
GAPDH levels in mock, or non-infected, HeLa and E. Derm
cells. Mock infected cells treated with the Akt Inhibitor VIII
showed a significant decrease in phosphorylated AKT sub-
strates compared with DMSO-only treated cells, decreasing
by 	37% ( 6%) in HeLa cells and by 	35% ( 19%) in E.
Derm cells (Fig. 6B).
Similarly, AHSV infection resulted in an increase of phos-
phorylated AKT substrates in HeLa cells by 	38% ( 16%),
and by 	37% ( 18%) in E. Derm cells (Fig. 6B). Akt Inhibitor
VIII treatment could significantly decrease the levels of phos-
phorylated AKT substrate in DMSO treated infected cells,
decreasing by 	37% ( 2%) in HeLa cells and by 	53% (
17%) in E. Derm cells. Following treatment with Akt Inhibitor
VIII, NS2 protein levels did not significantly decrease in either
HeLa cells nor in E. Derm cells and no observable decrease in
virus titer in the presence of the AKT inhibitor was detected
(supplemental Fig. S10E).
However, a previous body of work had reported that AKT
pathway activity decreased at 36 h.p.i., we set out to inves-
tigate this potential incongruity. We carried out a time-course
experiment, harvesting BTV and AHSV infected HeLa cells at
18 h.p.i, 24 h.p.i and 36 h.p.i. Cell lysates were analyzed by
Western blot (supplemental Fig. S9). At 18 h.p.i there is a
significant increase of phosphorylated AKT substrates in in-
fected HeLa cells when compared with mock infected cells
(	55% ( 15%)). However, the levels of phosphorylated AKT
substrates significantly decreased at 24 h.p.i and 36 h.p.i by
	71% ( 4%) and by 	62% ( 2%), respectively, compared
with infected cells analyses at 18 h.p.i. (Fig. 7A).
AHSV showed a different pattern in its profile of phos-
phorylated AKT substrates. At 18 h.p.i there is a significant
increase of phosphorylated AKT substrates in infected HeLa
cells (	34% ( 21%)). However, unlike BTV, we did not
observe a similar decrease, at 24 h.p.i and 36 h.p.i phos-
phorylated substrate levels remained 	51% ( 20%) and
	59% ( 8%), respectively, above the levels of mock infected
cells (Fig. 7B).
Together, these data suggest that the activation of the AKT
pathway occurs during infection by both orbiviruses. How-
ever, although AKT pathway activity significantly decreases
between 18 h.p.i and 36 h.p.i. for BTV, pathway activity re-
mains elevated for AHSV throughout the time points tested.
DISCUSSION
Reversible protein phosphorylation is the most pervasive
control and regulatory mechanism within cells to facilitate the
continual adjustment of catabolic, anabolic and signal trans-
duction events to maintain cellular equilibrium (36). The num-
ber of potential candidates is significant, given that it has been
estimated that up to 30% of expressed proteins contain at
least one covalently bound phosphate (37). This dynamic and
interconnected web of phosphorylated and dephosphoryl-
ated proteins is encapsulated within a cells phosphoproteome
and the examination for exploitation by viruses highly perti-
nent. Changes in the phosphoproteome of host cells during
infection provides an insight into the pathways exploited or
suppressed by a virus to facilitate successful propagation,
and its analysis may yield hitherto unknown or exploited op-
portunities for therapeutic interventions. Previously, several
other viruses have been studied in this way, including influ-
enza A virus (38), influenza B (39) and West Nile virus (40).
However, although proteomic studies have been carried out
for the family Reoviridae, using mammalian reoviruses (MRV)
(41), to date no global phosphoproteomic studies have inter-
rogated BTV infected cells prior to this study.
FIG. 7. AKT-dependent phosphorylated substrates decrease in
BTV1 infected cells but remain elevated in AHSV1 infected cells
between 18 and 36 h.p.i. HeLa cells infected with BTV1 (MOI  5)
(A) or HeLa cells infected with AHSV1 (MOI  5) (B) were har-
vested 18, 24, and 36 h.p.i. Densitometry analysis of phosphoryl-
ated-AKT substrates are expressed as relative protein level as indi-
cated. Error bars represent the S.D. values of stimulations from three
independent experiments. A star (*) denotes a significant difference
from control (p  0.05).
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Given that BTV is the prototype member of the Orbivirus
genus in the Reoviridae family, we set out to characterize the
phosphoproteome of HeLa cells infected with BTV at both
12 h.p.i and 18 h.p.i. During the subsequent analysis, we
confirmed that casein kinase 2 was active, this finding sup-
ports previous observations that delineated the significance
of this kinase and its activity for the phosphorylation of BTV
NS2 (13, 14). Furthermore, we could validate PKA as a novel
host cell factor utilized by both BTV and AHSV, whose target
substrates showed increased phosphorylation during infec-
tion at 18 h.p.i. Functional studies using a PKA inhibitor or a
PKA activator showed impaired or enhanced viral replication,
respectively, in both HeLa and sheep PT cells, a natural host
derived cell line. Concurrently, these results could be repli-
cated using AHSV, suggesting a broader role for PKA within
the Orbivirus genus. Inhibition of PKA prior to infection did not
result in a further reduction of viral replication, this contrasts
with observations made during studies of HCV, where inhibi-
tion of PKA led to a reduction in viral entry (17).
The modulation of the PKA pathway by BTV may correlate
to the role the PKA pathway plays in cell proliferation (42, 43)
by cell cycle arrest via p38 MAPK (44), impeding this process
for the reallocation of cellular resources into virus production.
In a recent study, the autophagy signaling network initiated
by BTV infection was examined at 24 h.p.i and 36 h.p.i (20).
The phosphorylation candidates that were examined, in-
cluded extra-cellular signal-regulated kinase 1/2 (ERK1/2),
p70S6K, mammalian target of rapamycin (mTOR) and AKT.
Although our study examines the phosphoproteome prior to
these time points, to avoid early CPE or cell death, it has
allowed us to compare our observations with these later
time points.
In this context, BTV mediated PKA activity could result in
the inhibition of extracellular signal-regulated kinase 1/2
(ERK1/2) activation (45, 46) which under certain circum-
stances has anti-apoptotic effects (47). Our phosphopro-
teomic analysis found that ERK1/2 activity was decreased at
18 h.p.i. ERK1/2 signaling pathway can promote cell survival
by mediating the phosphorylation of Bad and/or Bim through
multiple mechanisms, promoting cell proliferation and reduc-
ing the sensitivity of cells to apoptosis (48). The decreased
activity of ERK1/2 suggests an increased sensitivity of the
infected cells to apoptosis, which has previously been shown
to occur in BTV infected mammalian cells (49). However, with
regards to ERK1/2, Lv et al. found that there was no signifi-
cant difference between mock and BTV infected cells 36 h.p.i
(20).
FIG. 8. A schematic representation of pathways summary showing identified kinases in BTV infected cells. A, Protein kinase A (PKA)
activity may contribute to apoptosis inhibition and arrest of cell proliferation, extending the duration of viral replication. Validation experiments
confirmed the importance of PKA activity for BTV replication. B, BTV infection induces autophagy. Death-associated protein kinase 1 (DAPK1)
activity was identified and may contribute to autophagy induction during BTV infection. C, PAS Domain Containing Serine/Threonine Kinase
(PASK) activity increased during BTV infection, possibly increasing translation efficiency during viral protein synthesis. D, Apoptosis is known
to be controlled during BTV infection. Several kinases were identified as regulated by BTV infection which may contribute to the inhibition of
apoptosis, these include ribosomal protein S6 kinase beta-1 (p70S6K), ribosomal protein S6 kinase A1 and 3 (RPS6KA1 and 3), p21-activated
protein kinase 2 (PAK2), protein kinase C delta type (PKCD) activation and polo-like kinase 3 (PLK3). Inset shows various symbols:
phosphorylation events, pathway activation, inhibition and down-regulation. A yellow shadow shows known kinase activity and a purple
shadow depicts novel kinase activity.
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Our phosphoproteomic analysis also found that p70S6K
was active at both 12 h.p.i and 18 h.p.i. As p70S6K functions
to regulate protein synthesis (50, 51), this suggests that trans-
lation and protein synthesis could be enhanced within the
infected cells at these times. Furthermore, it may contribute to
the inhibition of apoptosis by the phosphorylation of the BCL2
associated agonist of cell death (Bad) protein (52). Interest-
ingly, p70S6K phosphorylation was found to be diminished
with increasing infection time, being 4.5 times lower at 36 h.p.i
(20), This, however, could be related to a host cell translational
shut-down at such a late time point (11).
In trying to dissect the autophagy induction network utilized
by BTV, it has been found that at 36 h.p.i, AKT diminished
(20). Our Motif-X analysis led us to examine changes in AKT
substrate phosphorylation. Our analysis, using Western blots,
showed significant increases in phosphorylate substrates at
18 h.p.i. However, a time-course experiment encompassing
18 h.p.i., 24 h.p.i., and 36 h.p.i revealed the subsequent
decrease in phosphorylated AKT substrates during BTV infec-
tion. These changes highlight the temporal and dynamic na-
ture of phosphoproteome during BTV infection, with AKT
being active during the early phase of infection before dimin-
ishing in the later stages. Strikingly, AHSV did not portray a
similarly dynamic nature.
Furthermore, the prospective novel kinases that this study
identified, including PAK2, PKCD, PASK, DAPK1, RPS6KA1
and 3, and PLK3, could also contribute to virus propagation
(Fig. 8). By activating PAK2, we hypothesis that BTV may
promote cell survival via the phosphorylation of caspase-7
(53), Bad and B-Cell CLL/Lymphoma 2 (Bcl-2) thereby
blocking apoptosis (54), which could allow for the extending
of the duration of virus replication within a cell. Similarly, the
upregulation of PKCD may also contribute to cell survival via
the AKT pathway (55). Furthermore, we speculate that ac-
tivation of PASK may enhance viral protein translation by
increasing translation efficiency through the phosphoryla-
tion of eukaryotic translation elongation factor 1 alpha 1
(EEF1A1) (56). Upregulation of DAPK1, although implicated
in pathways leading to apoptosis (57), has also been shown
to induce and regulate autophagy (58). Autophagy has pre-
viously been described in a proviral context with regards to
BTV replication (59). It could be hypothesized that DAPK1
activity may contribute to the induction of autophagy by
phosphorylation of protein kinase D (PKD) (60) and the
direct phosphorylation of Beclin1 (61), both of which act at
the induction stage of autophagosome nucleation via mod-
ulating the Vps34 class III phosphatidyl inositol 3-kinase
complex (58). Like PAK2 and PKCD, activation of RPS6KA1
and 3 could also contribute to cell survival and extending
the duration that BTV can replicate within a cell. Specifi-
cally, through the phosphorylation of BAD, which sup-
presses its pro-apoptotic function (62, 63). It can also be
hypothesized that the down-regulation of PLK3 may further
contribute to interfering with the induction of apoptosis via
a decreased ability to mediate P53 phosphorylation (64).
Interestingly, several of the novel kinases we identified,
and the pathways they regulate, appear to suppress apo-
ptosis at the times this study was carried out (12 h.p.i and
18 h.p.i). These observations agree with a previous study,
showing that the later stages of apoptosis, denoted by the
cleavage and inactivation of poly (ADP-ribose) polymerase
(PARP), only become detectable 24 h.p.i and onwards (65).
In conclusion, it is noteworthy that both BTV and AHSV,
with their distinct host range, require certain common host
factors (PKA), suggesting Orbiviruses may share some key
host factors and pathways during their infection. However,
these studies also showed their distinctiveness with regards
to their respective temporal phosphorylated AKT substrate
profiles. Interestingly, our phosphoproteomic analysis also
highlighted differences that might be relevant at later stages in
virus replication and pathogenesis.
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